作者: Li, Jianping ; Shen, Xiaoying ; Tomaras, Georgia D ; Breed, Matthew W ; Howe, Savannah E ; Sui, Yongjun ; Ma, Chi ; Berzofsky, Jay A ; Kramer, Josh A ; Cam, Maggie ; LaBranche, Celia C ; Meyer, Thomas J ; Dadkhah, Kimia ; Kelly, Michael C ; Miller, Christopher J ; Fennessey, Christine M ; Williams, LaTonya D ; Montefiori, David ; Keele, Brandon F ; Greten, Tim F ; Ferrari, Guido

Identifying immune correlates of protection is a major challenge in AIDS vaccine development. Anti-Envelope antibodies have been considered critical for protection against SIV/HIV (SHIV) acquisition. Here, we evaluated the efficacy of an SHIV vaccine against SIVmac251 challenge, where the role of antibody was excluded, as there was no cross-reactivity between SIV and SHIV envelope antibodies. After 8 low-dose intrarectal challenges with SIVmac251, 12 SHIV-vaccinated animals demonstrated efficacy, compared with 6 naive controls, suggesting protection was achieved in the absence of anti-envelope antibodies. Interestingly, CD8+ T cells (and some NK cells) were not essential for preventing viral acquisition, as none of the CD8-depleted macaques were infected by SIVmac251 challenges. Initial investigation of protective innate immunity revealed that protected animals had elevated pathways related to platelet aggregation/activation and reduced pathways related to interferon and responses to virus. Moreover, higher expression of platelet factor 4 on circulating platelet-leukocyte aggregates was associated with reduced viral acquisition. Our data highlighted the importance of innate immunity, identified mechanisms, and may provide opportunities for novel HIV vaccines or therapeutic strategy development.

2023-03-30·Journal of virology

The Failure of AIDS Vaccine Efficacy Trials: Where to Go from Here.

Article

作者: Desrosiers, Ronald C.

The seven AIDS vaccine efficacy trials have yielded extremely disappointing results at great expense. Greater stringency is needed for government support of AIDS vaccine efficacy trials.

2022-01-31·Human Vaccines & Immunotherapeutics3区 · 医学

HIV-1 genetic diversity a challenge for AIDS vaccine development: a retrospective bibliometric analysis

3区 · 医学

Article

作者: Ahmad, Tauseef ; Hu, Xiaoyan ; Yu, Yueyang ; Shao, Yiming ; Rashid, Abdur ; Getaneh, Yimam ; Abidi, Syed Hani ; Li, Kang ; Feng, Yi

BACKGROUNDDespite recent advances in human immunodeficiency virus-1 (HIV-1) prevention, a fast, safe, and effective vaccine will probably be necessary to end the HIV/AIDS pandemic. This study was conducted to evaluate global research trends and map the key bibliometric indices in HIV-1 genetic diversity from 1998 to 2021.METHODSA comprehensive online search was conducted in the Web of Science Core Collection database to retrieve published literature on HIV-1 genetic diversity. Key bibliometric indicators were calculated and evaluated using HistCite^TM, Bibliometrix: An R-tool, and VOSviewer software for windows.RESULTSA total of 2,060 documents written by 9,201 authors and published in 250 journals were included in the final analysis. Year 2012 was the most productive year with 121 (5.87%) publications. The most prolific author was Shao Yiming (n = 74, 3.59%) from Chinese Center for Disease Control and Prevention. The United States of America was the highly contributing and influential country (n = 681, 33.05%). AIDS Research and Human Retroviruses was the most productive journal (n = 562, 27.2%). Network visualization shows that HIV-1 was the most widely used author keyword.CONCLUSIONThis study provides global research trends and detailed information on HIV-1 genetic diversity. The amount of scientific literature on HIV-1 genetic diversity research has rapidly increased in the last two decades. The maximum number of articles on HIV-1 genetic diversity was published in developed countries; therefore, a scientific research collaboration among researchers and institutes in low-income countries should be promoted and supported.

100 项与 AIDS vaccine (Medestea) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HIV感染	临床1期	意大利	Medestea Internazionale Srl	2016-01-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


IAS2014	N/A	HIV感染	244	HIV vaccine (Participants with specified low-risk criteria)	簾夢簾糧願獵窪膚網鬱(願觸齋淵鹹製網糧鬱獵) = 糧蓋膚鏇獵選鏇襯襯簾廠遞艱衊膚鹽衊觸顧膚 (製鏇網觸繭襯夢餘網襯, 1.6 ~ 5.6)	-	2014-01-01
IAS2014	N/A	HIV感染	244	HIV vaccine (Participants without specified low-risk criteria)	簾夢簾糧願獵窪膚網鬱(願觸齋淵鹹製網糧鬱獵) = 壓夢選壓簾膚醖製淵鏇廠遞艱衊膚鹽衊觸顧膚 (製鏇網觸繭襯夢餘網襯, 0.3 ~ 4.0)	-	2014-01-01
IAS2006	N/A	HIV感染	1,200	HIV vaccine (Young people (<45 years))	獵築願簾齋醖餘繭淵遞(蓋糧選獵獵醖壓獵鹽蓋) = 艱艱選選製蓋繭構衊窪製窪鹽選遞鏇顧製襯顧 (構餘廠壓顧遞遞遞艱獵, 1.0 ~ 2.8)	-	2006-01-01
VAX004 (IAS2006)	N/A	-	37	Bivalent Glycoprotein (gp) 120 preventive HIV vaccine (High-risk uninfected women)	餘鑰憲醖範鬱鏇製襯網(齋鹹壓願壓壓襯獵憲構) = 顧壓壓鹽製願獵艱憲製範醖築鬱選獵夢齋齋選 (製簾選簾構醖網窪製憲, p=0.04)	-	2006-01-01
IAS2002	N/A	降低风险行为	-	HIV vaccine (AIDSVAX B/B)	鑰遞廠製繭齋遞簾醖繭(鏇簾範醖糧製製遞網願) = 顧壓獵顧繭艱簾壓窪襯糧壓鏇衊齋膚衊築醖構 (夢製鑰鬱廠簾鏇鹽淵觸 ) 更多	-	2002-01-01
IAS2002	N/A	降低风险行为	-	Placebo	鑰遞廠製繭齋遞簾醖繭(鏇簾範醖糧製製遞網願) = 膚膚鑰積獵選築壓糧範糧壓鏇衊齋膚衊築醖構 (夢製鑰鬱廠簾鏇鹽淵觸 ) 更多	-	2002-01-01